Mymetics Announces New Study to Predict Efficacy of Second-Generation COP Allergy Immunotherpy with Virosomes

EPALINGES, Switzerland, October 17th, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT), and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), announced the start of a new research study to evaluate the effects of the second generation virosome-based COP allergen immunotherapy in a therapeutic model of birch allergy in mice.

Media Name Media Type Description Download
Press Release PDF Download